Literature DB >> 18649176

Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury.

Simon J O'Carroll1, Mamoun Alkadhi, Louise F B Nicholson, Colin R Green.   

Abstract

Connexin 43 (Cx43) is up-regulated after spinal cord injury (SCI). The authors tested whether mimetic peptides, corresponding to short sequences of rat Cx43, would reduce the severity of damage in a rodent ex vivo model of SCI. Eleven peptides (peptides 1 to 11) corresponding to short amino acid sequences of the extracellular loops of rat Cx43 were tested. Two of these peptides, peptide 4 (corresponding to Gap27) and peptide 5, significantly reduced the degree of swelling after SCI in this model. Peptide 5 produced the more significant reduction in swelling and was analyzed further. Treatment with peptide 5 reduced both the level of Cx43 and the number of glial fibrillary acidic protein (GFAP)-positive astrocytes, and at the same time reduced the loss of NeuN-and SMI-32-positive neurons in a concentration-and time-dependent manner. In cell culture, low concentrations of peptide 5 prevented hemichannel opening, but did not disrupt gap junctional communication. Higher concentrations prevented hemichannel opening, but also uncoupled existing gap junctions. This study supports the idea that regulation of Cx43 hemichannel opening using mimetic peptides may be a useful treatment for reducing the spread of damage after SCI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18649176     DOI: 10.1080/15419060802014164

Source DB:  PubMed          Journal:  Cell Commun Adhes        ISSN: 1543-5180


  67 in total

Review 1.  Brain connexins in demyelinating diseases: therapeutic potential of glial targets.

Authors:  Maria Luisa Cotrina; Maiken Nedergaard
Journal:  Brain Res       Date:  2012-07-10       Impact factor: 3.252

2.  The lipidated connexin mimetic peptide SRPTEKT-Hdc is a potent inhibitor of Cx43 channels with specificity for the pS368 phospho-isoform.

Authors:  Maura L Cotter; Scott Boitano; Paul D Lampe; Joell L Solan; Josef Vagner; Jose F Ek-Vitorin; Janis M Burt
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-31       Impact factor: 4.249

3.  Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease.

Authors:  Odunayo O Mugisho; Colin R Green; David M Squirrell; Sarah Bould; Helen V Danesh-Meyer; Jie Zhang; Monica L Acosta; Ilva D Rupenthal
Journal:  J Mol Med (Berl)       Date:  2018-12-08       Impact factor: 4.599

4.  Non-additive effects of delayed connexin hemichannel blockade and hypothermia after cerebral ischemia in near-term fetal sheep.

Authors:  Joanne O Davidson; Alexandra L Rout; Guido Wassink; Caroline A Yuill; Frank G Zhang; Colin R Green; Laura Bennet; Alistair J Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-15       Impact factor: 6.200

5.  Novel Targets for Therapy of Renal Fibrosis.

Authors:  Niki Prakoura; Juliette Hadchouel; Christos Chatziantoniou
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

Review 6.  Gap junctions in inherited human disorders of the central nervous system.

Authors:  Charles K Abrams; Steven S Scherer
Journal:  Biochim Biophys Acta       Date:  2011-08-16

7.  Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS.

Authors:  Rohit Bisht; Abhirup Mandal; Ilva D Rupenthal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

8.  Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats.

Authors:  Yilin Mao; Tara Nguyen; Ryan S Tonkin; Justin G Lees; Caitlyn Warren; Simon J O'Carroll; Louise F B Nicholson; Colin R Green; Gila Moalem-Taylor; Catherine A Gorrie
Journal:  Exp Brain Res       Date:  2017-07-19       Impact factor: 1.972

9.  Connexin mimetic peptides inhibit Cx43 hemichannel opening triggered by voltage and intracellular Ca2+ elevation.

Authors:  Nan Wang; Marijke De Bock; Gudrun Antoons; Ashish K Gadicherla; Mélissa Bol; Elke Decrock; William Howard Evans; Karin R Sipido; Feliksas F Bukauskas; Luc Leybaert
Journal:  Basic Res Cardiol       Date:  2012-10-21       Impact factor: 17.165

10.  Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels.

Authors:  Yeri Kim; Jarred M Griffin; Mohd N Mat Nor; Jie Zhang; Peter S Freestone; Helen V Danesh-Meyer; Ilva D Rupenthal; Monica Acosta; Louise F B Nicholson; Simon J O'Carroll; Colin R Green
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.